PC(18:0/18:2(9Z,12Z))

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: PC(18:0/18:2(9Z,12Z))
• 英文别名: 2-[hydroxy-[(2R)-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxy-3-octadecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium
• 化学式: C44H85NO8P+
• 分子量: 787.1
• InChiKey: FORFDCPQKJHEBF-VPUSDGANSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  14.1
• 重原子数：
  54
• 可旋转键数：
  42
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• PHARMACEUTICAL COMPOSITIONS AND METHODS
  申请人：Pop Test Oncology Limited Liability Company

  公开号：US20170051007A1

  公开（公告）日：2017-02-23

  This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.
• Pharmaceutical Compositions and Methods
  申请人：Pop Test Oncology LLC

  公开号：US20170128465A1

  公开（公告）日：2017-05-11

  This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.
• US9598459B2
  申请人：——

  公开号：US9598459B2

  公开（公告）日：2017-03-21
• [EN] PHOSPHOLIPID COMPOSITIONS<br/>[FR] COMPOSITIONS DE PHOSOPHOLIPIDES
  申请人：MACHAVERT PHARMACEUTICALS LLC

  公开号：WO2018005735A9

  公开（公告）日：2018-02-01

  [EN] Compositions involving a modified egg yolk extract for use as an effective anti-cancer agent are described. The modified egg yolk extract involves specific fractions of phosphatidylcholines and sphingomyelins modified and produced from a chemical synthesis applied to the extract that produce a beneficial effect on the inhibition of cancerous cell growth. Methods of administering these compositions are also described.
  [FR] L'invention concerne des compositions comprenant un extrait de jaune d'oeuf modifié destiné à être utilisé en tant qu'agent anticancéreux efficace. L'extrait de jaune d'oeuf modifié comprend des fractions spécifiques de phosphatidylcholines et de sphingomyélines modifiées et produites à partir d'une synthèse chimique appliquée à l'extrait qui produisent un effet bénéfique sur l'inhibition de la croissance des cellules cancéreuses. L'invention concerne également des méthodes d'administration de ces compositions.